HER2-Low and HER2-Ultralow Breast Cancer — A Roundtable Discussion on Current and Future Management Strategies

Update: 2025-02-14

Description

Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, Dr Mark D Pegram from Stanford Cancer Institute in California, and Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, summarize currently available data guiding treatment decision-making for patients with low and ultralow HER2 expression and present cases from their practices.

CME information and select publications here.

Comments

In Channel

Bispecific Antibodies in Multiple Myeloma — An Interview with Dr Tiffany A Richards for Oncology Nurses

2025-03-2401:05:16

5-Minute Journal Club Issue 6 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

2025-03-2116:10

Neurofibromatosis Type 1 Plexiform Neurofibromas — An interview with Dr Christopher L Moertel

2025-03-2049:28

Bispecific Antibodies in Lymphoma Part 1 — An Interview with Ms Robin Klebig for Oncology Nurses

2025-03-1701:05:59

Renal Cell Carcinoma — Proceedings from a Session Held in Conjunction with the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU)

2025-03-1401:58:34

Colorectal Cancer — Year in Review Series on Relevant New Datasets and Advances

2025-03-1300:04

Localized Breast Cancer — Examining the Current Use of Genetic Testing and Related Clinical Management

2025-03-1159:49

Urothelial Bladder Cancer and Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU)

2025-03-0601:57:43

5-Minute Journal Club Issue 5 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

2025-02-2818:31

Biliary Tract Cancers — Reviewing Patient Cases with Prof John Bridgewater

2025-02-2758:00

$Relapsed/Refractory Diffuse Large B-Cell Lymphoma — A Roundtable Discussion on Current and Future Management Strategies$

Relapsed/Refractory Diffuse Large B-Cell Lymphoma — A Roundtable Discussion on Current and Future Management Strategies

2025-02-2102:33:01

Colorectal Cancer — Proceedings from a Session Held in Conjunction with the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI)

2025-02-2001:57:20

Multiple Myeloma — An Interview with Dr Surbhi Sidana on Optimizing the Role of CAR T-Cell Therapy

2025-02-1846:45

HER2-Low and HER2-Ultralow Breast Cancer — A Roundtable Discussion on Current and Future Management Strategies

2025-02-1402:02:17

Hepatocellular Carcinoma — Proceedings From a Session Held in Conjunction with the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI)

2025-02-1201:58:47

5-Minute Journal Club Issue 4 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

2025-02-0710:06

EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances

2025-02-0501:00:02

Multiple Myeloma — Optimizing the Selection of First-Line Therapy with Dr Saad Zafar Usmani

2025-02-0346:45

5-Minute Journal Club Issue 3 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

2025-01-3111:58

Chronic Lymphocytic Leukemia with Dr Jennifer Woyach: Part 3 of a 3-Part Meet The Professor Series

2025-01-2959:28

00:00

HER2-Low and HER2-Ultralow Breast Cancer — A Roundtable Discussion on Current and Future Management Strategies

#box-pro-ellipsis-176161965402251{-webkit-line-clamp:2;}HER2-Low and HER2-Ultralow Breast Cancer — A Roundtable Discussion on Current and Future Management Strategies

HER2-Low and HER2-Ultralow Breast Cancer — A Roundtable Discussion on Current and Future Management Strategies

Research To Practice

HER2-Low and HER2-Ultralow Breast Cancer — A Roundtable Discussion on Current and Future Management Strategies